The use of locoregional therapies in cholangiocarcinoma.

Locoregional therapies in cholangiocarcinoma show promising 3-year overall survival rates up to 50%, especially when combined with systemic treatments.

• Why it matters: Current standard treatments yield limited survival, highlighting the need for alternative approaches to improve outcomes for unresectable or advanced cholangiocarcinoma patients.
• What they did: A comprehensive review of clinical studies and ongoing trials evaluated locoregional therapies such as ablation, radiotherapy, and intra-arterial treatments in intrahepatic and perihilar cholangiocarcinoma, focusing on survival outcomes.
• The result: Findings suggest that integrating locoregional therapies with systemic treatments may enhance survival, but personalized, multidisciplinary strategies are essential until more randomized controlled trial data become available.